SuperworthAnika Therapeutics shares outstanding ANIK
Diluted shares outstanding, averaged over each quarter, from 2010.
- Latest quarter, to Jun 30, 2026
- 13.7M
- On a year earlier
- −5.5%
- fewer shares
Anika Therapeutics had 13.7M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 5.5% fewer than a year earlier, so each share owns a little more of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 14.3M | −2% |
| FY2024 | 14.6M | −0% |
| FY2023 | 14.6M | +0% |
| FY2022 | 14.6M | +1% |
| FY2021 | 14.4M | +1% |
| FY2020 | 14.3M | −2% |
| FY2019 | 14.6M | +2% |
| FY2018 | 14.3M | −6% |
| FY2017 | 15.1M | +1% |
| FY2016 | 15M | −2% |
| FY2015 | 15.4M | +0% |
| FY2014 | 15.3M | +1% |
| FY2013 | 15.1M | +5% |
| FY2012 | 14.3M | +4% |
| FY2011 | 13.8M | +0% |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 13.7M | −6% | |
| Q1 FY26 | 13.5M | −5% | |
| Q4 FY25 | 14.3M | −2% | |
| Q3 FY25 | 14.4M | −2% | |
| Q2 FY25 | 14.5M | −2% | |
| Q1 FY25 | 14.3M | −3% | |
| Q4 FY24 | 14.6M | −0% | |
| Q3 FY24 | 14.8M | +1% | |
| Q2 FY24 | 14.9M | +1% | |
| Q1 FY24 | 14.7M | +0% | |
| Q4 FY23 | 14.6M | +0% | |
| Q3 FY23 | 14.6M | +0% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Anika Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.